Marlen sells ZFGN 43.78: There currently are no approved medical therapies that fully address the biological mechanisms of obesity, and many patients are still beyond reach of meaningful treatment with current therapies.

Zafgen exclusively licensed beloranib from Chong Kun Dang (CKD) Pharmaceutical Corp. of South Korea. Zafgen holds exclusive worldwide rights (exclusive of South Korea) for the development and commercialization of beloranib. In this manner, MetAP2 inhibition increases metabolism of fat as an energy source. MetAP2 inhibitors work, at least in part, by directing MetAP2 binding to cellular stress mediators, and, thus, reducing the tone of signals that drive lipid synthesis by the liver and fat storage throughout the body. Beloranib is a potent inhibitor of methionine aminopeptidase 2, or MetAP2, an enzyme that modulates the activity of key cellular processes that control metabolism.


Eve:
Key secondary endpoints include changes in glycemic control, lipid parameters and inflammatory markers.

Corliss:
The primary efficacy endpoint is change in total body weight at six months of randomized treatment.

Patti:
Dennis Kim, Chief Medical Officer of Zafgen.

Venita:
Patients in the study are randomized to receive twice weekly subcutaneous injections of placebo, 1.2 mg or 1.8 mg of beloranib during the treatment period of 12 months.

Oretha:
The trial enrolled 152 patients across 16 sites in Australia.

Patricia:
Zafgen explicitly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Remona:
In addition, any forward-looking statements represent Zafgen's views only as of today and should not be relied upon as representing its views as of any subsequent date.

Glennis:
Zafgen is also developing ZGN-839, a liver-targeted MetAP2 inhibitor, for the treatment of nonalcoholic steatohepatitis, or NASH, and abdominal obesity, as well as second-generation MetAP2 inhibitors.

Danelle:
Goldberg sold 3,000 shares of the stock in a transaction on Wednesday, June 10th.

Elia:
In related news, Director Avi Y.

Zafgen Inc. (NASDAQ:ZFGN)
//stockhand.net/us/?q=nasdaq%3Azfgn&id=486640